Cepheid (CPHD +4.8%) gets a boost from a Goldman upgrade to buy, noting the company's new...

|By:, SA News Editor

Cepheid (CPHD +4.8%) gets a boost from a Goldman upgrade to buy, noting the company's new product opportunities, increased global TB testing, and improved top-line growth.